The pharmaceutical and biotechnology sectors were dominated by the Covid-19 pandemic in 2020, which promoted a surge of research and business activity. But with multiple vaccines in circulation, biopharma is an area to watch in the coming year.
What's ahead for pharma and biotech litigation?
Burford VP Joshua Harris explains what's ahead for pharma and biotech litigation.
Burford's Joshua Harris, Vice President with responsibility for assessing and underwriting legal risk, focusing on patent and intellectual property matters, has been consecutively named as one of the world's leading IP strategists by the IAM Strategy 300. In this video, he explains what's ahead for pharma and biotech litigation:
- The major trends and developments in the pharmaceutical and biotech sectors in 2020
- The impact of the Covid-19 pandemic on drug development pipelines
- The implications for the patent sector as we move in 2021 and beyond